Every 8-K that Enovis Corporation (ENOV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENOV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENOV filings page.
Enovis Corporation (ENOV) announced a binding offer to acquire eCential Robotics SAS, a developer of enabling technologies and surgical robotics, to expand its ASTRA™ technology platform and robotics capabilities. The deal values eCential at an enterprise value of €155 million, with upfront cash consideration of €176 million to be paid to eCential shareholders at closing.
The agreement also includes up to €35 million in additional contingent cash consideration tied to milestone achievements. Enovis plans to fund the transaction with cash on hand and availability under its existing revolving credit facility. Closing is expected by year-end 2026, subject to regulatory approvals and French works council consultation.
Enovis expects the acquisition to cause approximately 150 basis points of deal-related dilution to Adjusted EBITDA margin in 2027, partially offset by about 50 basis points of underlying margin improvement, resulting in a net 100 basis point headwind in 2027. Free cash flow conversion is expected to rise to 50% in 2027, to over $100 million, with further improvement anticipated in 2028 and 2029.
Enovis Corporation reported second-quarter 2026 net sales of $582.8 million, up from $564.5 million a year earlier, driven by 7.5% reported growth in Reconstructive while Prevention & Recovery was roughly flat on a reported basis but grew 3.5% organically.
The company posted a small GAAP net loss of $1.0 million (0.2% of sales), but generated adjusted net income of $52.2 million and adjusted diluted EPS of $0.90. Adjusted EBITDA rose to $104.3 million, a 17.9% margin, compared with $91.2 million and a 16.2% margin in the prior-year quarter.
For 2026, Enovis reaffirmed guidance for revenue of $2.31–$2.37 billion with 4–6% organic growth, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free cash flow conversion of at least 25%.
Enovis Corporation reported the results of its Annual Meeting held on May 19, 2026. Stockholders approved an amendment to the 2020 Omnibus Incentive Plan that authorizes an additional 3,650,000 shares of common stock for equity awards and raises the annual compensation cap for each Outside Director from $350,000 to $750,000, with up to 200% of that limit allowed in certain first-year or leadership appointment situations.
All ten director nominees were elected, each receiving over 50 million votes in favor with relatively few votes against. Stockholders ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers. The plan amendment will be implemented through a Form S-8 registration of the additional shares.
Enovis Corporation reported higher first-quarter 2026 sales while remaining loss-making on a GAAP basis but stronger on adjusted metrics. Net sales were $589.2 million, up 5.4% year over year and 3.3% organically, driven by 10.8% reported growth in Reconstructive, while Prevention & Recovery was flat.
The company posted a GAAP net loss of $8.5 million, a net margin of (1.4)%, but generated adjusted net income from continuing operations of $51.6 million, or $0.89 per diluted share, up from $0.65 a year earlier. Adjusted EBITDA was $103.6 million, representing a 17.6% margin versus 15.6% last year.
Enovis reaffirmed its full-year 2026 outlook, expecting revenue of about $2.31–$2.37 billion, incorporating 4–6% organic growth, adjusted EBITDA of $425–$435 million, adjusted EPS of $3.52–$3.73, and free cash flow conversion of 25% or higher.
Enovis Corporation reported fourth-quarter and full-year 2025 results showing steady growth but a large accounting loss driven by goodwill impairment. Fourth-quarter net sales were $575.8 million, up 2.6%, with Reconstructive up 6.9% and Prevention & Recovery roughly flat. Adjusted EBITDA for the quarter was $111.9 million and adjusted diluted EPS was $0.95.
For 2025, net sales reached $2.248 billion, up 6.7% on a reported basis and 5.9% organically. Reconstructive grew 10%, while Prevention & Recovery grew 3.6%. The company recorded a full-year net loss from continuing operations of $1,182 million, or $20.72 per share, largely due to a non-cash goodwill impairment charge of $1,049.8 million. Adjusted EBITDA was $403.0 million and adjusted diluted EPS was $3.30.
Enovis generated $217.3 million in operating cash flow in 2025 and modestly reduced debt. For 2026, it expects revenue of $2.31–2.37 billion with 4–6% organic growth, adjusted EBITDA of $425–435 million, and adjusted EPS of $3.52–3.73.
Enovis Corporation filed a current report to highlight that its management team is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST (7:30 p.m. EST). The company states that a live webcast of the presentation and the related slide deck will be accessible through its website at www.enovis.com, with a replay available later the same day.
The slide presentation used at the conference is also furnished as Exhibit 99.1. Enovis notes that these presentation materials are being furnished to the SEC and are not deemed incorporated by reference into its Securities Act filings.
Enovis Corporation reported a planned leadership transition in its human resources function. Senior Vice President and Chief Human Resources Officer Patricia A. Lang informed the board she intends to retire from her current role on April 3, 2026, then serve in an advisory position until her full retirement from the company on April 3, 2027.
Enovis expects to appoint Laura Singleton, currently Vice President of Human Resources for the Reconstructive segment, as the new Senior Vice President and Chief Human Resources Officer effective April 3, 2026. Singleton joined Enovis in 2019 through its acquisition of DJO Global and has held multiple senior HR roles, and she holds a B.A. in history from Texas State University.
The company and Ms. Lang entered into a retirement transition agreement covering the period from April 3, 2026 through April 3, 2027. During this time, she will receive her current base salary for six months, after which it may be reduced by up to 50% for the remainder of the transition period, while remaining eligible for existing benefit plans and the annual incentive plan based on her actual base pay. The full agreement will be filed with Enovis’s Form 10-K for the year ended December 31, 2025.
Enovis Corporation entered into a Third Amendment to its existing credit agreement, updating the terms of its main debt facilities. The amended agreement provides a revolving credit facility of up to $1.1 billion and a $700.0 million term loan facility, and extends the maturity date for both to December 8, 2030, with an earlier maturity if, 91 days before that date, the company’s liquidity is less than 125% of the principal on its senior unsecured convertible notes.
The amendment keeps the required maximum Senior Secured Leverage Ratio at 3.50 to 1.00, but allows a temporary higher ratio after one or more acquisitions with aggregate consideration of $300.0 million or more, down from the prior $500.0 million threshold. It also increases the amount of unrestricted cash that can offset debt in leverage calculations to $400.0 million, from $150.0 million, reduces interest margins when the Total Leverage Ratio is below 1.50 to 1.00, and raises the cap on consideration for certain permitted acquisitions from $150.0 million to $200.0 million.
As of December 8, 2025, after applying the new terms, Enovis used part of the term loan proceeds to repay about $335.0 million of revolving borrowings, leaving $167.0 million outstanding under the revolving facility and $700.0 million outstanding under the term loan facility. Additional banks, including Truist Bank, DNB Capital LLC and Sumitomo Mitsui Banking Corporation, joined as lenders under the amended agreement.
Enovis Corporation filed an 8-K announcing it issued a press release with financial results for the third quarter ended October 3, 2025.
The company scheduled a conference call for 8:30 a.m. Eastern on November 6, 2025 to discuss these results. The press release is included as Exhibit 99.1.
Enovis Corporation (ENOV) filed a Form 8-K on 7 Aug 2025 to furnish Item 2.02 information. The filing states that a press release detailing Q2 FY25 results (quarter ended 4 Jul 2025) was issued the same day and is included as Exhibit 99.1. Management will host a conference call at 8:30 a.m. ET on 7 Aug 2025 to discuss those results. No financial figures, guidance, or qualitative commentary are provided within the 8-K itself. Exhibit 104 indicates the cover page is formatted in Inline XBRL.
The 8-K therefore serves solely as a procedural furnishing of the earnings release and does not, on its own, reveal performance metrics or forward-looking statements.